Drug Profile
Research programme: toll-like receptor 9 agonists - Aceragen/Merck KGaA
Latest Information Update: 20 Jan 2023
Price :
$50
*
At a glance
- Originator Idera Pharmaceuticals
- Developer Aceragen; Merck KGaA
- Class
- Mechanism of Action Toll-like receptor 9 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer